Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry

Infliximab and golimumab are intravenously (IV) administered tumor necrosis factor inhibitors approved to treat moderate-to-severe rheumatoid arthritis (RA) with concomitant methotrexate. Owing to differences in biologic construct, patients with IV-infliximab treatment failure may benefit from switc...

Descripción completa

Detalles Bibliográficos
Autores principales: Tesser, John, Lin, Iris, Shiff, Natalie J., Chakravarty, Soumya D., Schmajuk, Gabriela, Hammam, Nevin, Desai, Sheetal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287251/
https://www.ncbi.nlm.nih.gov/pubmed/35312895
http://dx.doi.org/10.1007/s10067-022-06116-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287251/
https://www.ncbi.nlm.nih.gov/pubmed/35312895
http://dx.doi.org/10.1007/s10067-022-06116-z

Ejemplares similares